BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Tseng HC, Xiong W, Badeti S, Yang Y, Ma M, Liu T, Ramos CA, Dotti G, Fritzky L, Jiang JG, Yi Q, Guarrera J, Zong WX, Liu C, Liu D. Efficacy of anti-CD147 chimeric antigen receptors targeting hepatocellular carcinoma. Nat Commun 2020;11:4810. [PMID: 32968061 DOI: 10.1038/s41467-020-18444-2] [Cited by in Crossref: 10] [Cited by in F6Publishing: 13] [Article Influence: 5.0] [Reference Citation Analysis]
Number Citing Articles
1 Fan C, Kam S, Ramadori P. Metabolism-Associated Epigenetic and Immunoepigenetic Reprogramming in Liver Cancer. Cancers (Basel) 2021;13:5250. [PMID: 34680398 DOI: 10.3390/cancers13205250] [Reference Citation Analysis]
2 Liao CG, Liang XH, Ke Y, Yao L, Liu M, Liu ZK, He L, Guo YX, Bian H, Chen ZN, Kong LM. Active demethylation upregulates CD147 expression promoting non-small cell lung cancer invasion and metastasis. Oncogene 2022. [PMID: 35132181 DOI: 10.1038/s41388-022-02213-0] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Karvouni M, Vidal-Manrique M, Lundqvist A, Alici E. Engineered NK Cells Against Cancer and Their Potential Applications Beyond. Front Immunol 2022;13:825979. [PMID: 35242135 DOI: 10.3389/fimmu.2022.825979] [Reference Citation Analysis]
4 Nai Y, Du L, Shen M, Li T, Huang J, Han X, Luo F, Wang W, Pang D, Jin A. TRAIL-R1-Targeted CAR-T Cells Exhibit Dual Antitumor Efficacy. Front Mol Biosci 2021;8:756599. [PMID: 34988114 DOI: 10.3389/fmolb.2021.756599] [Reference Citation Analysis]
5 Maggs L, Cattaneo G, Dal AE, Moghaddam AS, Ferrone S. CAR T Cell-Based Immunotherapy for the Treatment of Glioblastoma. Front Neurosci 2021;15:662064. [PMID: 34113233 DOI: 10.3389/fnins.2021.662064] [Reference Citation Analysis]
6 Bashiri Dezfouli A, Yazdi M, Pockley AG, Khosravi M, Kobold S, Wagner E, Multhoff G. NK Cells Armed with Chimeric Antigen Receptors (CAR): Roadblocks to Successful Development. Cells 2021;10:3390. [PMID: 34943898 DOI: 10.3390/cells10123390] [Reference Citation Analysis]
7 Wang K, Wang C, Jiang H, Zhang Y, Lin W, Mo J, Jin C. Combination of Ablation and Immunotherapy for Hepatocellular Carcinoma: Where We Are and Where to Go. Front Immunol 2021;12:792781. [PMID: 34975896 DOI: 10.3389/fimmu.2021.792781] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
8 Roddy H, Meyer T, Roddie C. Novel Cellular Therapies for Hepatocellular Carcinoma. Cancers (Basel) 2022;14:504. [PMID: 35158772 DOI: 10.3390/cancers14030504] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
9 Huang T, He W. Pan-Cancer Analysis, Reveals COVID-19-Related BSG as a Novel Marker for Treatment and Identification of Multiple Human Cancers. Front Cell Dev Biol 2022;10:876180. [DOI: 10.3389/fcell.2022.876180] [Reference Citation Analysis]
10 Sawaisorn P, Atjanasuppat K, Anurathapan U, Chutipongtanate S, Hongeng S. Strategies to Improve Chimeric Antigen Receptor Therapies for Neuroblastoma. Vaccines (Basel) 2020;8:E753. [PMID: 33322408 DOI: 10.3390/vaccines8040753] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
11 Zheng N, Zhao X, Wei D, Miao J, Liu Z, Yong Y, Zhang R, Guo Y, He L, Wang B, Sun X, Yang H, Zhang T, He Q, Li X, Zhang H, Hou R, Lin P, Xu Y, Huang X, Chen Z, Bian H. CD147-specific chimeric antigen receptor T cells effectively inhibit T cell acute lymphoblastic leukemia. Cancer Letters 2022. [DOI: 10.1016/j.canlet.2022.215762] [Reference Citation Analysis]
12 Dong S, Li S, Wang X, Liang S, Zhang W, Li L, Xu Q, Shi B, Cheng Z, Zhang X, Zhong M, Zhang G, Hu S. CD147 Mediates 5-Fluorouracil Resistance in Colorectal Cancer by Reprogramming Glycolipid Metabolism. Front Oncol 2022;12:813852. [DOI: 10.3389/fonc.2022.813852] [Reference Citation Analysis]
13 Luginbuehl V, Abraham E, Kovar K, Flaaten R, Müller AM. Better by design: What to expect from novel CAR-engineered cell therapies? Biotechnol Adv 2022;:107917. [PMID: 35149146 DOI: 10.1016/j.biotechadv.2022.107917] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
14 Hao X, Sun G, Zhang Y, Kong X, Rong D, Song J, Tang W, Wang X. Targeting Immune Cells in the Tumor Microenvironment of HCC: New Opportunities and Challenges. Front Cell Dev Biol 2021;9:775462. [PMID: 34869376 DOI: 10.3389/fcell.2021.775462] [Reference Citation Analysis]
15 Dai K, Wu Y, She S, Zhang Q. Advancement of chimeric antigen receptor-natural killer cells targeting hepatocellular carcinoma. World J Gastrointest Oncol 2021; 13(12): 2029-2037 [DOI: 10.4251/wjgo.v13.i12.2029] [Reference Citation Analysis]
16 Xue C, Gu X, Li L. Immune classifier-based signatures provide good prognostic stratification and predict the clinical benefits of immune-based therapies for hepatocellular carcinoma. Cancer Cell Int 2021;21:471. [PMID: 34488768 DOI: 10.1186/s12935-021-02183-5] [Reference Citation Analysis]
17 Lawal G, Xiao Y, Rahnemai-Azar AA, Tsilimigras DI, Kuang M, Bakopoulos A, Pawlik TM. The Immunology of Hepatocellular Carcinoma. Vaccines (Basel) 2021;9:1184. [PMID: 34696292 DOI: 10.3390/vaccines9101184] [Reference Citation Analysis]
18 Sakamoto M, Miyagaki T, Kamijo H, Oka T, Boki H, Takahashi-Shishido N, Suga H, Sugaya M, Sato S. CD147-Cyclophilin a Interactions Promote Proliferation and Survival of Cutaneous T-Cell Lymphoma. Int J Mol Sci 2021;22:7889. [PMID: 34360654 DOI: 10.3390/ijms22157889] [Reference Citation Analysis]
19 Zhang C, Shi Y, Wu L, Wang C, Liao N, Wang F, Zhao B, Wang Y, Liu X. Far-Red Light Triggered Production of Bispecific T Cell Engagers (BiTEs) from Engineered Cells for Antitumor Application. ACS Synth Biol 2022;11:888-99. [PMID: 35113526 DOI: 10.1021/acssynbio.1c00523] [Reference Citation Analysis]
20 Feng Y, Liu M, Xie P, Dong R, Hao Z. FBXO31 suppresses lipogenesis and tumor progression in glioma by promoting ubiquitination and degradation of CD147. Prostaglandins & Other Lipid Mediators 2022. [DOI: 10.1016/j.prostaglandins.2022.106667] [Reference Citation Analysis]
21 Li R, Zhu X, Zhou P, Qiao Y, Li Y, Xu Y, Shi X. Generation of a High-Affinity Nanobody Against CD147 for Tumor Targeting and Therapeutic Efficacy Through Conjugating Doxorubicin. Front Immunol 2022;13:852700. [PMID: 35603157 DOI: 10.3389/fimmu.2022.852700] [Reference Citation Analysis]
22 Wang Z, Wen P, Hu B, Cao S, Shi X, Guo W, Zhang S. Dopamine and dopamine receptor D1 as a novel favourable biomarker for hepatocellular carcinoma. Cancer Cell Int 2021;21:586. [PMID: 34717619 DOI: 10.1186/s12935-021-02298-9] [Reference Citation Analysis]
23 Marofi F, Al-Awad AS, Sulaiman Rahman H, Markov A, Abdelbasset WK, Ivanovna Enina Y, Mahmoodi M, Hassanzadeh A, Yazdanifar M, Stanley Chartrand M, Jarahian M. CAR-NK Cell: A New Paradigm in Tumor Immunotherapy. Front Oncol 2021;11:673276. [PMID: 34178661 DOI: 10.3389/fonc.2021.673276] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
24 Jacquelot N, Seillet C, Souza-Fonseca-Guimaraes F, Sacher AG, Belz GT, Ohashi PS. Natural Killer Cells and Type 1 Innate Lymphoid Cells in Hepatocellular Carcinoma: Current Knowledge and Future Perspectives. Int J Mol Sci 2021;22:9044. [PMID: 34445750 DOI: 10.3390/ijms22169044] [Reference Citation Analysis]
25 Sajid M, Liu L, Sun C. The Dynamic Role of NK Cells in Liver Cancers: Role in HCC and HBV Associated HCC and Its Therapeutic Implications. Front Immunol 2022;13:887186. [PMID: 35669776 DOI: 10.3389/fimmu.2022.887186] [Reference Citation Analysis]
26 Alnefaie A, Albogami S, Asiri Y, Ahmad T, Alotaibi SS, Al-sanea MM, Althobaiti H. Chimeric Antigen Receptor T-Cells: An Overview of Concepts, Applications, Limitations, and Proposed Solutions. Front Bioeng Biotechnol 2022;10:797440. [DOI: 10.3389/fbioe.2022.797440] [Reference Citation Analysis]
27 Ma Y, Sun W, Zhang Q, Gao B, Cai W, Liu Q, Liao J, Wang X. lncRNA BSG-AS1 is hypoxia-responsive and promotes hepatocellular carcinoma by enhancing BSG mRNA stability. Biochem Biophys Res Commun 2021;566:101-7. [PMID: 34119821 DOI: 10.1016/j.bbrc.2021.06.002] [Reference Citation Analysis]
28 Baghery Saghchy Khorasani A, Yousefi AM, Bashash D. CAR NK cell therapy in hematologic malignancies and solid tumors; obstacles and strategies to overcome the challenges. Int Immunopharmacol 2022;110:109041. [PMID: 35839565 DOI: 10.1016/j.intimp.2022.109041] [Reference Citation Analysis]
29 Wu H, Li W, Hao M, Wang Y, Xue L, Ju C, Zhang C. An EPR-Independent Extravasation Strategy: Deformable Leukocytes as Vehicles for Improved Solid Tumor Therapy. Adv Drug Deliv Rev 2022;:114380. [PMID: 35662610 DOI: 10.1016/j.addr.2022.114380] [Reference Citation Analysis]
30 Mylod E, Lysaght J, Conroy MJ. Natural killer cell therapy: A new frontier for obesity-associated cancer. Cancer Lett 2022;535:215620. [PMID: 35283210 DOI: 10.1016/j.canlet.2022.215620] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
31 Hosseini M, Habibi Z, Hosseini N, Abdoli S, Rezaei N. Preclinical studies of chimeric antigen receptor-modified natural killer cells in cancer immunotherapy: a review. Expert Opin Biol Ther 2021;:1-18. [PMID: 34541989 DOI: 10.1080/14712598.2021.1983539] [Reference Citation Analysis]
32 Rabal O, San José-enériz E, Agirre X, Sánchez-arias JA, de Miguel I, Ordoñez R, Garate L, Miranda E, Sáez E, Vilas-zornoza A, Pineda-lucena A, Estella A, Zhang F, Wu W, Xu M, Prosper F, Oyarzabal J. Design and Synthesis of Novel Epigenetic Inhibitors Targeting Histone Deacetylases, DNA Methyltransferase 1, and Lysine Methyltransferase G9a with In Vivo Efficacy in Multiple Myeloma. J Med Chem 2021;64:3392-426. [DOI: 10.1021/acs.jmedchem.0c02255] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
33 Liu Z, Liu X, Liang J, Liu Y, Hou X, Zhang M, Li Y, Jiang X. Immunotherapy for Hepatocellular Carcinoma: Current Status and Future Prospects. Front Immunol 2021;12:765101. [PMID: 34675942 DOI: 10.3389/fimmu.2021.765101] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
34 Gallage S, García-beccaria M, Szydlowska M, Rahbari M, Mohr R, Tacke F, Heikenwalder M. The therapeutic landscape of hepatocellular carcinoma. Med 2021;2:505-52. [DOI: 10.1016/j.medj.2021.03.002] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
35 Pan C, Zhai Y, Li G, Jiang T, Zhang W. NK Cell-Based Immunotherapy and Therapeutic Perspective in Gliomas. Front Oncol 2021;11:751183. [PMID: 34765554 DOI: 10.3389/fonc.2021.751183] [Reference Citation Analysis]
36 Zhang C, Zhuang Q, Liu J, Liu X. Synthetic Biology in Chimeric Antigen Receptor T (CAR T) Cell Engineering. ACS Synth Biol 2022;11:1-15. [PMID: 35005887 DOI: 10.1021/acssynbio.1c00256] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
37 Marofi F, Abdul-Rasheed OF, Rahman HS, Budi HS, Jalil AT, Yumashev AV, Hassanzadeh A, Yazdanifar M, Motavalli R, Chartrand MS, Ahmadi M, Cid-Arreguid A, Jarahian M. CAR-NK cell in cancer immunotherapy; A promising frontier. Cancer Sci 2021;112:3427-36. [PMID: 34050690 DOI: 10.1111/cas.14993] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 4.0] [Reference Citation Analysis]
38 Xu X, Mao Y, Tang Y, Liu Y, Xue C, Yue Q, Liu Q, Wang J, Yin Y, Yang J. Classification of Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma Based on Radiomic Analysis. Computational and Mathematical Methods in Medicine 2022;2022:1-9. [DOI: 10.1155/2022/5334095] [Reference Citation Analysis]